Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2020
SIETES contiene 93010 citas

 
 
<< anterior 21 a 40 de 55 siguiente >>
Presentar resultados
Seleccionar todas
21.
Anis AH, Guh D, Hogg RS, Wang XH, Yip B, Craib KJP, O'Shaughnessy MV, Schechter MT, Montaner JSG. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 2000;18:393-404. [Ref.ID 52997]
22. Cita con resumen
Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 2000;356:1003-4. [Ref.ID 52790]
23.Tiene citas relacionadas
Blayac JP. Comment: opiate withdrawal symptoms induced by antiretroviral drugs. Author's reply. Ann Pharmacother 2000;34:1078. [Ref.ID 52745]
24.Tiene citas relacionadas
Eap CB. Comment: opiate withdrawal symptoms induced by antiretroviral drugs. Ann Pharmacother 2000;34:1077-8. [Ref.ID 52744]
25.Tiene citas relacionadas
Danoff A, Ling WLW. Protease inhibitors and prohormone processing. In response. Ann Intern Med 2000;133:483. [Ref.ID 52644]
26.Tiene citas relacionadas
Stricker RB, Goldberg B. Protease inhibitors and prohormone processing. Ann Intern Med 2000;133:482-3. [Ref.ID 52643]
27. Cita con resumen
Anónimo. Abacavir (Ziagen®) y reacciones de hipersensibilidad: nuevas medidas. PAM 2000;24:580,613. [Ref.ID 52625]
28.
29. Cita con resumen
Anónimo. Principales interactions médicamenteuses des antirétroviraux. Prescrire 2000;20:599-601. [Ref.ID 52588]
30. Cita con resumen
Anónimo. Early pivotal data hint a Kaletra benefit. Scrip 2000;2569:20. [Ref.ID 52503]
31. Cita con resumen
Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107. [Ref.ID 52358]
32.
Figgitt DP, Plosker G L. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000;60:481-516. [Ref.ID 52267]
33.
Hervey PS, Perry C M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000;60:447-79. [Ref.ID 52266]
34.
Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80. [Ref.ID 52218]
35.
Anónimo. Drug interactions with St John's wort. Med Lett Drugs Ther 2000;42:56. [Ref.ID 51982]
38.
Delgado Fernández M, Zambrana García JL, Díez García F. A common problem with therapy for HIV infection. Ann Intern Med 2000;132:846. [Ref.ID 51964]
39.
Dumon C, Solas C, Thuret I, Chambost H, Lacarelle B, Michel G, Durand A. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit 2000;22:402-8. [Ref.ID 51926]
40. Cita con resumen
Fernández Sánchez E, Aznar Saliente T, Camacho Romera D, González Montero R. Evolución de la terapia antirretroviral en pacientes pediátricos VIH+. Aten Farmaceutica 2000;2:234-8. [Ref.ID 51898]
Seleccionar todas
 
<< anterior 21 a 40 de 55 siguiente >>